Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$379,022.00
Feb 10, 2026
For-profit organization
Development of INT-101 formulation for human dosing and prevention of diabetes
1040017
Development of INT-101 formulation for human dosing and prevention of diabetes
$506,250.00
Apr 15, 2024
For-profit organization
Evaluation of a tolerogenic LNP (lipid nanoparticle) formulation to treat type 1 diabetes in a mouse model of type 1 diabetes
1018412
Evaluation of a tolerogenic LNP (lipid nanoparticle) formulation to treat type 1 diabetes in non-obese diabetic (NOD) mice, an established mouse model of type 1 diabetes.
$50,000.00
Apr 1, 2023
For-profit organization
ICAP 2022 – International Co-Innovation Action Plan
1005568
ICAP 2022 – International Co-Innovation Action Plan
$4,166.00
Oct 21, 2022
For-profit organization
CIIP PDA – Integrated Nanotherapeutics Inc.– 2022-23
7444827 P012264001
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
$77,176.00
Oct 16, 2021
For-profit organization
Development of tolerogenic lipid nanoparticle (LNP) formulation containing messenger ribonucleic acid (mRNA)
982040
Development of lipid nanoparticles (LNP) encasing mRNA for vaccines.
$36,000.00
Jun 1, 2020
For-profit organization
Youth - Research Associate, Formulations
973281
Development of immunomodulatory formulations for inflammatory diseases
$193,456.00
Dec 16, 2019
For-profit organization
Lipid nanoparticle drugs for immunomodulatory therapy of autoimmune/inflammatory disease
940510
This project aims to develop effective immunomodulatory formulations to induce immune tolerance as a therapeutic strategy for autoimmune and inflammatory diseases.
$4,140.00
Sep 9, 2019
For-profit organization
CXI - Integrated Nanotherapeutics Inc. 2019-2020
7411471 P008226001
The purpose of this CanExport Innovation (CXI) grant agreement is to support organizations and to build on targeted relationships between Canadian companies/researchers and key organizations in other countries to allow them to proceed with formal discussions to initiate collaboration(s) on future international R&D initiatives that could lead to commercialization of Canadian technologies.
$100,000.00
Mar 18, 2019
For-profit organization
000015341
000015341
Develop and market novel therapies for the treatment of diabetes
$131,560.00
Jul 1, 2018
For-profit organization
Development of lipid nanoparticulate drugs for immunotolerogenic therapy of autoimmune/inflammatory disease
909840
This project aims to develop effective immunomodulatory formulations to induce immune tolerance as a therapeutic strategy for autoimmune and inflammatory diseases.